Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis
Ivan T Lee, Raffael Nachbagauer, David Ensz, Howard Schwartz, Lizbeth Carmona, Kristi Schaefers, Andrei Avanesov, Daniel Stadlbauer, Carole Henry, Ren Chen, Wenmei Huang, Daniela Ramirez Schrempp, Jintanat Ananworanich, Robert Paris, Ivan T Lee, Raffael Nachbagauer, David Ensz, Howard Schwartz, Lizbeth Carmona, Kristi Schaefers, Andrei Avanesov, Daniel Stadlbauer, Carole Henry, Ren Chen, Wenmei Huang, Daniela Ramirez Schrempp, Jintanat Ananworanich, Robert Paris
Abstract
Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadrivalent messenger RNA (mRNA) vaccine against seasonal influenza, mRNA-1010, from the first 2 parts of a 3-part, first-in-human, phase 1/2 clinical trial in healthy adults aged ≥18 years (NCT04956575). In the placebo-controlled Part 1, a single dose of mRNA-1010 (50 µg, 100 µg, or 200 µg) elicited hemagglutination inhibition (HAI) titers against vaccine-matched strains. In the active-comparator-controlled Part 2, mRNA-1010 (25 µg, 50 µg, or 100 µg) elicited higher HAI titers than a standard dose, inactivated seasonal influenza vaccine for influenza A strains and comparable HAI titers for influenza B strains. No safety concerns were identified; solicited adverse reactions were dose-dependent and more frequent after receipt of mRNA-1010 than the active comparator. These interim data support continued development of mRNA-1010.
Conflict of interest statement
I.L., R.N., L.C., K.S., A.A., D.S., C.H., R.C., W.H., D.R.S., J.A., and R.P. are employees of and shareholders in Moderna, Inc. D.E. and H.S. declare no competing interests.
© 2023. The Author(s).
Figures
References
- Cowling BJ, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin. Infect. Dis. 2020;71:1704–1714. doi: 10.1093/cid/ciz1034.
- World Health Organization. Vaccines against influenza: WHO position paper—May 2022. Weekly Epidemiological Record.19, 185–208 (2022).
- Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nat. Med. 2019;25:212–220. doi: 10.1038/s41591-018-0340-z.
- Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2020–21 Influenza Season. (2021).
- Luliano AD, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–1300. doi: 10.1016/S0140-6736(17)33293-2.
- Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J. Virol. 2014;88:7692–7695. doi: 10.1128/JVI.03544-13.
- Walker TA, et al. Risk of severe influenza among adults with chronic medical conditions. J. Infect. Dis. 2020;221:183–190. doi: 10.1093/infdis/jiz570.
- Centers for Disease Control and Prevention. Flu & people 65 years and older. (2022).
- Paget J, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. J. Glob. Health. 2019;9:020421. doi: 10.7189/jogh.09.020421.
- McElhaney JE, et al. The immune response to influenza in older humans: beyond immune senescence. Immun. Ageing. 2020;17:10. doi: 10.1186/s12979-020-00181-1.
- Centers for Disease Control and Prevention. Types of influenza viruses. (2021).
- Chivukula S, et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines. 2021;6:153. doi: 10.1038/s41541-021-00420-6.
- Nachbagauer R, Palese P. Is a universal influenza virus vaccine possible. Annu. Rev. Med. 2020;71:315–327. doi: 10.1146/annurev-med-120617-041310.
- Centers for Disease Control and Prevention. Vaccine effectiveness: how well do flu vaccines work? (2022).
- Chung JR, et al. Interim estimates of 2021-22 seasonal influenza vaccine effectiveness—United States, February 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:365–370. doi: 10.15585/mmwr.mm7110a1.
- Zost SJ, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA. 2017;114:12578–12583. doi: 10.1073/pnas.1712377114.
- Takada K, et al. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Nat. Microbiol. 2019;4:1268–1273. doi: 10.1038/s41564-019-0433-6.
- Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243.
- Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021;6:1078–1094. doi: 10.1038/s41578-021-00358-0.
- United States Food and Drug Administration. Package Insert - SPIKEVAX. (2022).
- Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.
- Bruxvoort, K. J. et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study. Lancet Reg. Health Am. 100134, 10.1016/j.lana.2021.100134 (2021).
- Bruxvoort KJ, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021;375:e068848. doi: 10.1136/bmj-2021-068848.
- Tseng HF, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 2022;28:1063–1071. doi: 10.1038/s41591-022-01753-y.
- Cox RJ. Correlates of protection to influenza virus, where do we go from here. Hum. Vaccine Immunother. 2013;9:405–408. doi: 10.4161/hv.22908.
- Dolgin E. mRNA flu shots move into trials. Nat. Rev. Drug Discov. 2021;20:801–803. doi: 10.1038/d41573-021-00176-7.
- Raymond DD, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat. Med. 2016;22:1465–1469. doi: 10.1038/nm.4223.
- Lederer K, et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity. 2020;53:1281–1295.e1285. doi: 10.1016/j.immuni.2020.11.009.
- Turner JS, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109–113. doi: 10.1038/s41586-021-03738-2.
- Goel RR, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829. doi: 10.1126/science.abm0829.
- Mateus J, et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science. 2021;374:eabj9853. doi: 10.1126/science.abj9853.
Source: PubMed